Treatment of inflammatory diseases with mesenchymal stem cells.

Human mesenchymal stem cells (hMSCs) are rare progenitor cells present in adult bone marrow that have the capacity to differentiate into a variety of tissue types, including bone, cartilage, tendon, fat, and muscle. In addition to multilineage differentiation capacity, MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component. The availability of bone marrow and the ability to isolate and expand hMSCs ex vivo make these cells an attractive candidate for drug development. The low immunogenicity of these cells suggests that hMSCs can be transplanted universally without matching between donors and recipients. MSCs universality, along with the ability to manufacture and store these cells long-term, present a unique opportunity to produce an "off-the-shelf" cellular drug ready for treatment of diseases in acute settings. Accumulated animal and human data support MSC therapeutic potential for inflammatory diseases. Several phase III clinical trials for treatment of acute Graft Versus Host Disease (GVHD) and Crohn's disease are currently in progress. The current understanding of cellular and molecular targets underlying the mechanisms of MSCs action in inflammatory settings as well as clinical experience with hMSCs is summarized in this review.

[1]  B. Blanco,et al.  The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes , 2008, Haematologica.

[2]  P. Veys,et al.  Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. , 2008, Blood.

[3]  L. Ortiz,et al.  Stem cells and cell therapies in lung biology and lung diseases. , 2008, Proceedings of the American Thoracic Society.

[4]  T. Ben-Hur,et al.  Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. , 2008, Archives of neurology.

[5]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[6]  V. Barnaba,et al.  Immunogenicity of Human Mesenchymal Stem Cells in HLA‐Class I‐Restricted T‐Cell Responses Against Viral or Tumor‐Associated Antigens , 2008, Stem cells.

[7]  E. Jones,et al.  Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies , 2008, Mechanisms of Ageing and Development.

[8]  L. Moretta,et al.  Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. , 2008, Blood.

[9]  A. Martini,et al.  Bone Marrow‐Derived Mesenchymal Stem Cells Induce Both Polyclonal Expansion and Differentiation of B Cells Isolated from Healthy Donors and Systemic Lupus Erythematosus Patients , 2008, Stem cells.

[10]  F. Montecucco,et al.  Human Mesenchymal Stem Cells Inhibit Neutrophil Apoptosis: A Model for Neutrophil Preservation in the Bone Marrow Niche , 2008, Stem cells.

[11]  N. Rouas-Freiss,et al.  Human Leukocyte Antigen‐G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells , 2008, Stem cells.

[12]  L. Cosmi,et al.  Toll‐Like Receptors 3 and 4 Are Expressed by Human Bone Marrow‐Derived Mesenchymal Stem Cells and Can Inhibit Their T‐Cell Modulatory Activity by Impairing Notch Signaling , 2008, Stem cells.

[13]  J. Rossignol,et al.  A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. , 2007, Blood.

[14]  A. Caplan Adult mesenchymal stem cells for tissue engineering versus regenerative medicine , 2007, Journal of cellular physiology.

[15]  Franco Locatelli,et al.  Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. , 2007, Blood.

[16]  V. Levitsky,et al.  Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes , 2007, Journal of leukocyte biology.

[17]  C. van Kooten,et al.  The action of interleukin 6 on lymphoid populations. , 2007, Ciba Foundation symposium.

[18]  W. Friedrich,et al.  Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. , 2007, Blood.

[19]  O. Ringdén,et al.  No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients , 2007, Haematologica.

[20]  F. Djouad,et al.  Mesenchymal Stem Cells Inhibit the Differentiation of Dendritic Cells Through an Interleukin‐6‐Dependent Mechanism , 2007, Stem cells.

[21]  J. Ryan,et al.  Interferon‐γ does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells , 2007 .

[22]  L. Fouillard,et al.  Immunosuppressive Effects of Mesenchymal Stem Cells: Involvement of HLA-G , 2007, Transplantation.

[23]  E. Petricoin,et al.  Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. , 2007, Blood.

[24]  G. Mancardi,et al.  Human Mesenchymal Stem Cells Promote Survival of T Cells in a Quiescent State , 2007, Stem cells.

[25]  A. Poggi,et al.  Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. , 2007, Haematologica.

[26]  N. Gallay,et al.  The In Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells: Comparison of Chemokine and Growth Factor Chemotactic Activities , 2007, Stem cells.

[27]  L. Ortiz,et al.  Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury , 2007, Proceedings of the National Academy of Sciences.

[28]  M. Cerinic,et al.  Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. , 2007, Arthritis and rheumatism.

[29]  M. Endres,et al.  Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2 , 2007, Journal of cellular biochemistry.

[30]  K. Ozawa,et al.  Interferon-γ and NF-κB mediate nitric oxide production by mesenchymal stromal cells , 2007 .

[31]  O. Ringdén,et al.  Mesenchymal Stem Cells Stimulate Antibody Secretion in Human B Cells , 2007, Scandinavian journal of immunology.

[32]  A. Poncelet,et al.  Although Pig Allogeneic Mesenchymal Stem Cells Are Not Immunogenic In Vitro, Intracardiac Injection Elicits an Immune Response In Vivo , 2007, Transplantation.

[33]  T. Rème,et al.  Bone marrow mesenchymal stem cells are abnormal in multiple myeloma , 2007, Leukemia.

[34]  Antonio Uccelli,et al.  Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis , 2007, Annals of neurology.

[35]  Ly Sun,et al.  Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus , 2007, Lupus.

[36]  A. Cometa,et al.  Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[37]  R. Willemze,et al.  Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. , 2006, Blood.

[38]  M. Yacoub,et al.  Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. , 2006, Tissue engineering.

[39]  Anoop P. Patel,et al.  Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. , 2006, Blood.

[40]  I. Ghiran,et al.  Human Bone Marrow Stromal Cells Express a Distinct Set of Biologically Functional Chemokine Receptors , 2006, Stem cells.

[41]  L. Moretta,et al.  Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. , 2006, Blood.

[42]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[43]  S. Perez,et al.  Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells , 2006, Stem cells.

[44]  L. Lejeune,et al.  Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. , 2005, Blood.

[45]  D. Prockop,et al.  Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Torella,et al.  Cardiac Stem Cells Possess Growth Factor-Receptor Systems That After Activation Regenerate the Infarcted Myocardium, Improving Ventricular Function and Long-Term Survival , 2005, Circulation research.

[47]  G. Mancardi,et al.  Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.

[48]  M. Richard,et al.  Mesenchymal stem cells induce apoptosis of activated T cells , 2005, Leukemia.

[49]  O. Koç,et al.  Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. , 2005, Experimental hematology.

[50]  E. Bonifacio,et al.  Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. , 2005, Blood.

[51]  P. Rameshwar,et al.  A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge. , 2005, Experimental hematology.

[52]  Yi Zhang,et al.  Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. , 2005, Blood.

[53]  R. Cancedda,et al.  Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway , 2005, European journal of immunology.

[54]  Andrea Bacigalupo,et al.  Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[55]  F. Djouad,et al.  Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. , 2005, Arthritis and rheumatism.

[56]  O. Ringdén,et al.  Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. , 2005, Experimental cell research.

[57]  E. Lam,et al.  Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. , 2005, Blood.

[58]  D. Mevorach,et al.  Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. , 2005, Blood.

[59]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[60]  R. Gazzinelli,et al.  Role of the Toll/interleukin‐1 receptor signaling pathway in host resistance and pathogenesis during infection with protozoan parasites , 2004, Immunological reviews.

[61]  J. Chan,et al.  Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy , 2004, The Lancet.

[62]  M. Pittenger,et al.  Mesenchymal stem cells and their potential as cardiac therapeutics. , 2004, Circulation research.

[63]  Roland Meisel,et al.  Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. , 2004, Blood.

[64]  Shu-Ching Hsu,et al.  Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  S. T. Dheen,et al.  Interactions of Chemokines and Chemokine Receptors Mediate the Migration of Mesenchymal Stem Cells to the Impaired Site in the Brain After Hypoglossal Nerve Injury , 2004, Stem cells.

[66]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[67]  J. Borneman,et al.  Mesenchymal stem cells home to injured tissues when co‐infused with hematopoietic cells to treat a radiation‐induced multi‐organ failure syndrome , 2003, The journal of gene medicine.

[68]  O. Ringdén,et al.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells , 2003, Transplantation.

[69]  P. Rameshwar,et al.  Veto-Like Activity of Mesenchymal Stem Cells: Functional Discrimination Between Cellular Responses to Alloantigens and Recall Antigens1 , 2003, The Journal of Immunology.

[70]  D. Prockop,et al.  One strategy for cell and gene therapy: Harnessing the power of adult stem cells to repair tissues , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Krampera,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[72]  C. Cobbs,et al.  Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. , 2003, Blood.

[73]  M. Sanz,et al.  Anaphylactic reaction after artificial insemination. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[74]  J. Mosca,et al.  Characterization and functionality of cell surface molecules on human mesenchymal stem cells. , 2003, Journal of biomedical science.

[75]  E. Guinan,et al.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.

[76]  M. Chopp,et al.  Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. , 2002, Experimental hematology.

[77]  J. Wagner,et al.  Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[78]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[79]  D J Prockop,et al.  Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[80]  W. Mars,et al.  Bone marrow as a potential source of hepatic oval cells. , 1999, Science.

[81]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[82]  J. Westwick,et al.  Chemokines: understanding their role in T-lymphocyte biology. , 1998, The Biochemical journal.

[83]  S. Bruder,et al.  Growth kinetics, self‐renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation , 1997, Journal of cellular biochemistry.

[84]  A. Caplan Mesenchymal Stem Cells , 1991, Cartilage.

[85]  J. Wal,et al.  Bovine serum albumin immunization: a new risk of allergy during protocols for in vitro fertilization , 1991, Allergy.

[86]  H. Colten,et al.  Immediate hypersensitivity to hog trypsin resulting from industrial exposure. , 1975, The New England journal of medicine.

[87]  A. Friedenstein,et al.  STROMAL CELLS RESPONSIBLE FOR TRANSFERRING THE MICROENVIRONMENT OF THE HEMOPOIETIC TISSUES: Cloning In Vitro and Retransplantation In Vivo , 1974, Transplantation.

[88]  Bin Zhang,et al.  Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. , 2009, Blood.

[89]  J. Wagner,et al.  Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I–II clinical trial , 2009, Bone Marrow Transplantation.

[90]  L. Fouillard,et al.  Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. , 2008, Cellular immunology.

[91]  K. Ozawa,et al.  Interferon-gamma and NF-kappaB mediate nitric oxide production by mesenchymal stromal cells. , 2007, Biochemical and biophysical research communications.

[92]  Kazuya Sato,et al.  Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. , 2007, Blood.

[93]  J. Soulier,et al.  Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma , 2007, Leukemia.

[94]  Sergio Romagnani,et al.  Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.

[95]  F. Benvenuto,et al.  Human mesenchymal stem cells modulate B-cell functions. , 2006, Blood.

[96]  R. Willemze,et al.  Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34 -Derived and Monocyte-Derived Dendritic Cells , 2006 .

[97]  A. Cometa,et al.  Inherited thrombocytopenias: from genes to therapy , 1994 .

[98]  J. Mosca,et al.  T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. , 2005, Journal of biomedical science.

[99]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.

[100]  Kevin McIntosh,et al.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. , 2002, Experimental hematology.

[101]  K. Le Blanc [Mesenchymal stem cells. Basic science and future clinical use]. , 2002, Läkartidningen.

[102]  E. Ordoqui,et al.  Anaphylactic shock caused by impurities in orgotein preparations. , 2001, Allergologia et Immunopathologia.

[103]  R. Biassoni,et al.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. , 2001, Annual review of immunology.

[104]  A I Caplan,et al.  Characterization of cells with osteogenic potential from human marrow. , 1992, Bone.